30 Oct 2018 --- The use of BASF’s Hepaxa can correct nutritional deficiencies of omega 3 fatty acid in patients with non-alcoholic fatty liver disease (NAFLD), thereby offering a viable option for managing the condition, a BASF study has found. Several studies have previously shown that NAFLD patients have lower levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which are in omega 3. The findings from the study support the use of BASF's Hepaxa for managing NAFLD.
